Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
Neuropace Inc. (NPCE) filed a Current Report on Form 8-K dated June 4, 2025. The filing announces the entry into a new material definitive credit agreement and the concurrent termination of its existing term loan agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
The filing details a refinancing transaction involving the following key terms:
- New Term Loan: $60 million facility, fully funded at closing.
- New Revolver: Asset-based revolving credit facility up to $15 million (subject to borrowing base).
- Maturity Date: June 4, 2030 for both facilities.
- Interest Rates:
- Term Loan: SOFR + 5.50% (SOFR floor 2.00%).
- Revolver: SOFR + 3.75% (SOFR floor 2.00%).
- Unused Line Fee: 0.25% per annum on the Revolver.
- Prepayment Premiums: 3.00% (Year 1), 2.00% (Year 2), 1.00% (Year 3), 0.00% thereafter.
- Repayment of Prior Debt: Approximately $61.9 million (principal, interest, and fees) repaid under the existing loan agreement.
Material Changes Versus Prior Period
The primary material change is the replacement of the existing Term Loan Agreement (originally dated September 24, 2020) with a new Credit Agreement. This transaction extends the maturity of the company's senior secured debt from the prior agreement's terms to June 2030. The new agreement introduces specific financial covenants tied to liquidity and revenue targets that were not present in the same form in the prior agreement.
Guidance, Covenants, and Risks
The new Credit Agreement includes specific financial covenants and conditions:
- Liquidity Covenant: Requires minimum liquidity of $25 million at all times. This covenant is waived if the company achieves at least $90 million in RNS Systems commercial revenue in 2026.
- Revenue Covenant: If liquidity falls below specific thresholds (starting at $60 million, decreasing to $40 million after June 30, 2027, or $35 million if the 2026 revenue target is met), the company must achieve a minimum amount of Net RNS Revenue during the quarter.
- Collateral: The loans are secured by a first lien on substantially all existing and after-acquired assets of the company and its material subsidiaries.
- Use of Proceeds: Term Loan proceeds used to repay existing indebtedness; Revolver proceeds for general working capital and corporate purposes.
Note: The filing does not provide specific revenue, profit, or cash flow figures for the current period, as this is a transactional report rather than a periodic financial report.
Investor Verification Checklist
- Verify the exact amount of cash on hand and liquidity immediately following the $61.9 million repayment and $60 million new funding.
- Confirm the company's progress toward the $90 million RNS Systems revenue target for 2026, which triggers covenant relief.
- Review the full text of the Credit Agreement (to be filed as an exhibit to the Q2 2025 Form 10-Q) for detailed negative covenants and events of default.
- Monitor the SOFR rate environment to assess the impact of the floating interest rate structure on future interest expense.